TIDM0A45
Moderna Inc
07 December 2023
Moderna Reviews its Environmental, Social and Governance (ESG)
Progress and Ambitions at Second ESG Investor Event
The Company's ESG strategy demonstrates its efforts to advance
global health and environmental sustainability, as well as its
commitments to employees and communities
CAMBRIDGE, MA / ACCESSWIRE / December 7, 2023 / Moderna, Inc.
(NASDAQ:MRNA) today will provide an update on its Environmental,
Social and Governance (ESG) strategy at its second ESG Investor
Event. Building off its inaugural ESG Day in November 2022, the
Company will highlight the year's progress on its ESG journey and
future work to further impact global health and protect the
environment.
"Our mRNA platform science has benefited patients around the
world and with that comes great responsibility as science alone
will not solve the world's greatest health challenges," said
Stéphane Bancel, Chief Executive Officer of Moderna. "We are
committed to moving beyond the power of our technology - tackling
enduring health disparities, engaging with our communities, and
recognizing that human health and planetary health are intricately
linked. We look forward to building on our substantial ESG progress
to become the best version of Moderna."
Moderna's ESG strategy is articulated around five areas:
-- Medicines for Patients: Moderna is leveraging its platform
for many medicines, from vaccines to protect hundreds of millions
of people from common viruses for which no vaccines are available
today, to several rare disease therapies with tremendous
opportunity for impact. Within its clinical trials, Moderna
believes a committed approach to offering equal healthcare
accessibility is achievable and necessary. The Company is also
committed to using its platform to help rapidly respond to the
greatest public health threats, pursuing a pipeline of priority
programs relevant for outbreak response and pandemic preparedness.
Moderna has long prioritized strategic collaborations to benefit
global health, including its partnership with The Coalition for
Epidemic Preparedness Innovations (CEPI), and Moderna's mRNA Access
program, a collaborative effort that enables researchers around the
world to utilize Moderna's mRNA technology.
-- Environment: Moderna is progressing on its journey toward
net-zero carbon emissions (Scopes 1 & 2) by 2030. The Company
has advanced its overall environmental sustainability program,
including through implementing its sustainability strategy,
enhancing its disclosure of key performance indicators, submitting
its first CDP Climate Change questionnaire, and initiating a
climate risk and scenario analysis. These efforts support internal
and external stakeholder expectations for sustainable operations
and Moderna's adaptation to a low-carbon economy.
-- Employees & Culture: Moderna consistently ranks as a top
employer and achieves above benchmark scores on engagement, culture
and belonging. Moderna continues to foster a culture where every
employee can meaningfully contribute to the Company's mission, an
effort that serves to attract and retain the best talent. By living
the Company's values and mindsets every day, the Moderna team is
not only advancing mRNA science, but also building an organization
that cares deeply for patients, employees, the environment, and the
community.
-- Community: Moderna is committed to having a positive impact
on communities around the world. Moderna's purpose-driven employees
continue to exemplify the Company's mission, with nearly two out of
three employees participating in volunteering activities or
contributing as part of Moderna's newly instituted employee
matching program. The Moderna Charitable Foundation continues to
provide financial support to organizations and causes that promote
public health, advance scientific education, and advocate for
belonging, inclusion, and diversity.
-- Governance & Ethics: Moderna prioritizes accountability
and transparency around its ESG efforts, including through the
publication of its second annual ESG report and continued
commitment to disclosing key metrics. Moderna has initiated an ESG
materiality assessment, which includes broad stakeholder surveys,
and is also leveraging AI to build a dynamic analysis of material
topics.
"Delivering on our ESG ambitions is made possible by a strong
culture that embeds the values of transparency, accountability and
ownership at all levels of the organization," said Shannon Thyme
Klinger, Moderna's Chief Legal Officer, Corporate Secretary and
President of the Moderna Foundation. "The same determination that
goes into our innovation carries over into our commitment to
positively impact the communities in which we work and live."
Webcast Information
To register for the live webcast of Moderna's ESG Investor
Event, visit
https://moderna-esg-day-2023.open-exchange.net/registration . The
archived webcast will be available under "Events and Presentations"
in the Investors section of the Moderna website for one year
following the call: https://investors.modernatx.com .
About Moderna
Moderna is a leader in the creation of the field of mRNA
medicine. Through the advancement of mRNA technology, Moderna is
reimagining how medicines are made and transforming how we treat
and prevent disease for everyone. By working at the intersection of
science, technology and health for more than a decade, the company
has developed medicines at unprecedented speed and efficiency,
including one of the earliest and most effective COVID-19
vaccines.
Moderna's mRNA platform has enabled the development of
therapeutics and vaccines for infectious diseases, immuno-oncology,
rare diseases and autoimmune diseases. With a unique culture and a
global team driven by the Moderna values and mindsets to
responsibly change the future of human health, Moderna strives to
deliver the greatest possible impact to people through mRNA
medicines. For more information about Moderna, please visit
modernatx.com and connect with us on X (formerly Twitter),
Facebook, Instagram, YouTube and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including statements regarding: Moderna's ability
to leverage its mRNA platform for pandemic preparedness; Moderna's
commitment to achieving net-zero carbon emissions in its global
operations for Scopes 1 and 2 by 2030; the potential of Moderna's
mRNA platform for addressing rare diseases and common viruses for
which no vaccines are available today; and Moderna's implementation
of its environmental sustainability program. The forward-looking
statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties, and other factors, many of which are beyond
Moderna's control and which could cause actual results to differ
materially from those expressed or implied by these forward-looking
statements. These risks, uncertainties, and other factors include,
among others, those risks and uncertainties described under the
heading "Risk Factors" in Moderna's Annual Report on Form 10-K for
the fiscal year ended December 31, 2022, filed with the U.S.
Securities and Exchange Commission (SEC), and in subsequent filings
made by Moderna with the SEC, which are available on the SEC's
website at www.sec.gov . Except as required by law, Moderna
disclaims any intention or responsibility for updating or revising
any forward-looking statements contained in this press release in
the event of new information, future developments or otherwise.
These forward-looking statements are based on Moderna's current
expectations and speak only as of the date of this press
release
Moderna Contacts
Media:
Chris Ridley
Vice President, Communications
617-800-3651
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZMGZGVMGFZZ
(END) Dow Jones Newswires
December 07, 2023 07:00 ET (12:00 GMT)
Moderna (LSE:0A45)
Historical Stock Chart
From Oct 2024 to Nov 2024
Moderna (LSE:0A45)
Historical Stock Chart
From Nov 2023 to Nov 2024
